An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension
An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension is a paper indexed in ScholarIQ from OpenAlex.
How many citations does An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension have?
An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension has 2 citations in the OpenAlex counts ScholarIQ stores.
When was An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension published?
An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension has 2006 year in the ScholarIQ index.
What is the open-access status of An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension?
An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension has bronze oa status in the ScholarIQ index.
What is the DOI of An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension?
The DOI for An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension is on the source record.
What is the PMID of An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension?
The PMID for An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension is on the source record.
What is the OpenAlex record for An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension?
The OpenAlex for An Open-label, Randomized, Controlled, 4-week Comparative Clinical Trial of Barnidipine Hydrochloride, a Calcium-channel Blocker, and Benazepril, an Angiotensin-converting Enzyme Inhibitor, in Chinese Patients with Renal Parenchymal Hypertension is on the source record.